pazopanib

Also known as PZP034, GW 786034, indazolylpyrimidine 13, GW 78603, GW786034

Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.

Key facts

Drug.S: 1
Drug.ATC_suffix: EX03
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.C: 21
Drug.H: 23
Drug.N: 7
Drug.O: 2
Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 464197511
Drug.image: Pazopanib.svg
Drug.image_class: skin-invert-image
Drug.width: 275
Drug.tradename: Votrient

via Wikipedia infobox

Research

2,767 papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet (London, England) · 2012
Drug review: Pazopanib.Japanese journal of clinical oncology · 2018
Pazopanib in ovarian cancer.Expert review of anticancer therapy · 2015
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.Expert opinion on investigational drugs · 2019
Pazopanib: a Review in Advanced Renal Cell Carcinoma.Targeted oncology · 2017

via PubMed

~2 min read

Encyclopedic overview

9 sections

Contents

Medical uses
Contraindications
Adverse effects
Overdose
Interactions
Pharmacology
Mechanism of action
Pharmacokinetics
References

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464197511 | image = Pazopanib.svg | image_class = skin-invert-image | width = 275 | alt =

Excerpted from Wikipedia’s “pazopanib” article, available under the CC BY-SA 4.0 licence.

Available in 16 languages

via Wikidata sitelinks · CC0